SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oncolytics Biotech Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: geoffb_si who wrote (78)4/28/2002 5:07:35 PM
From: DaveAu  Read Replies (1) of 103
 
Geoff,

Good points regarding the genetically engineered viruses and the reovirus being resistant to mutation due to being double stranded.

You're probably also right about the need for some phase 2 data before institutions get interested although phase 1 often doesn't provide any efficacy info and the ONC phase 1 did and it was pretty convincing - at least that the reovirus can shrink tumours although it doesn't answer the more important question of whether that leads to extension of life.

I have to disagree however that we will see any efficacy data from the phase 2 trials this year, at least not from the Glio trial. Don't forget how long the phase 1 trial took. I guess they could release some interim data on the prostate trial because the trial is essentially over for each patient once they take out the prostate but I know how long the researchers take to putz around with the data.

Dave
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News